Promising cancer combo trial halted after just 7 patients
NCT ID NCT05921760
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This early-phase trial tested a three-drug combination (ivosidenib, nivolumab, and ipilimumab) in 7 people with advanced bile duct cancer that has a specific IDH1 mutation. The goal was to check safety and find the right dose, but the study was stopped early by the sponsor before it could test how well the treatment works. Only safety information is available.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
ivosidenib, nivolumab, and ipilimumab
What this could lead to
If it had succeeded, this combination could have pointed toward a new treatment option for a rare bile duct cancer with a specific gene mutation.
What could go wrong
The trial was terminated early after only 7 participants, so we have very little data. The combination may cause serious side effects, and it is unclear if it would work at all.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for IDH1-MUTANT CHOLANGIOCARCINOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Dana Farber Cancer Institute
Boston, Massachusetts, 02215, United States
-
Sidney Kimmel Comprehensive Cancer Center At Johns Hopkins
Baltimore, Maryland, 21231, United States
-
UCLH
London, NW1 2PG, United Kingdom
-
UCSF - Medical Center at Mission Bay
San Francisco, California, 94158, United States
-
Ucsf Helen Diller Family Comprehensive Cancer Center
San Francisco, California, 94158, United States